BACKGROUND: Allogeneic HSCT is highly effective for treating ALL. However, many ALL patients relapse after HSCT. There has been a continuing effort to improve identification of patients at high risk of relapse, with the goal of early intervention to improve outcome. PATIENTS AND METHODS: In this retrospective analysis, we examined the effect of MRD on the risk of hematologic relapse in 149 adult patients with ALL in morphologic remission undergoing allogeneic HSCT. MRD was assessed at the time of HSCT and after HSCT. RESULTS: Patients with pretransplant MRD had a trend for shorter progression-free survival (PFS) at 2 years compared with patients without MRD, nearing statistical significance; 28% versus 47%, P = .08, on univariate analysis. This trend remained on multivariate analysis with better PFS in patients without MRD at the time of HSCT, hazard ratio (HR), 0.62 (95% confidence interval, 0.37-1.04); P = .07. Additionally, emergence of MRD after HSCT was a strong predictor for overt hematologic relapse (HR, 4; P < .001) with a median latency interval of 3.8 months. CONCLUSION: These findings demonstrate the predictive value of monitoring for MRD around the time of transplant in adult patients with ALL. Published by Elsevier Inc.
BACKGROUND: Allogeneic HSCT is highly effective for treating ALL. However, many ALL patients relapse after HSCT. There has been a continuing effort to improve identification of patients at high risk of relapse, with the goal of early intervention to improve outcome. PATIENTS AND METHODS: In this retrospective analysis, we examined the effect of MRD on the risk of hematologic relapse in 149 adult patients with ALL in morphologic remission undergoing allogeneic HSCT. MRD was assessed at the time of HSCT and after HSCT. RESULTS:Patients with pretransplant MRD had a trend for shorter progression-free survival (PFS) at 2 years compared with patients without MRD, nearing statistical significance; 28% versus 47%, P = .08, on univariate analysis. This trend remained on multivariate analysis with better PFS in patients without MRD at the time of HSCT, hazard ratio (HR), 0.62 (95% confidence interval, 0.37-1.04); P = .07. Additionally, emergence of MRD after HSCT was a strong predictor for overt hematologic relapse (HR, 4; P < .001) with a median latency interval of 3.8 months. CONCLUSION: These findings demonstrate the predictive value of monitoring for MRD around the time of transplant in adult patients with ALL. Published by Elsevier Inc.
Authors: V H van der Velden; S A Joosten; M J Willemse; E R van Wering; A W Lankester; J J van Dongen; P M Hoogerbrugge Journal: Leukemia Date: 2001-09 Impact factor: 11.528
Authors: A J Barrett; M M Horowitz; R C Ash; K Atkinson; R P Gale; J M Goldman; P J Henslee-Downey; R H Herzig; B Speck; F E Zwaan Journal: Blood Date: 1992-06-01 Impact factor: 22.113
Authors: Jianbiao Zhou; Meredith A Goldwasser; Aihong Li; Suzanne E Dahlberg; Donna Neuberg; Hongjun Wang; Virginia Dalton; Kathryn D McBride; Stephen E Sallan; Lewis B Silverman; John G Gribben Journal: Blood Date: 2007-05-07 Impact factor: 22.113
Authors: Forida Y Mortuza; Mary Papaioannou; Ilidia M Moreira; Luke A Coyle; Paula Gameiro; Domenica Gandini; H Grant Prentice; Anthony Goldstone; A Victor Hoffbrand; Letizia Foroni Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta Journal: Blood Date: 2008-04-03 Impact factor: 22.113
Authors: P Bader; J Hancock; H Kreyenberg; N J Goulden; D Niethammer; A Oakhill; C G Steward; R Handgretinger; J F Beck; T Klingebiel Journal: Leukemia Date: 2002-09 Impact factor: 11.528
Authors: Orietta Spinelli; Barbara Peruta; Manuela Tosi; Vittoria Guerini; Anna Salvi; Maria Cristina Zanotti; Elena Oldani; Anna Grassi; Tamara Intermesoli; Caterina Micò; Giuseppe Rossi; Pietro Fabris; Giorgio Lambertenghi-Deliliers; Emanuele Angelucci; Tiziano Barbui; Renato Bassan; Alessandro Rambaldi Journal: Haematologica Date: 2007-05 Impact factor: 9.941
Authors: J R Wingard; S Piantadosi; G W Santos; R Saral; H M Vriesendorp; A M Yeager; W H Burns; R F Ambinder; H G Braine; G Elfenbein Journal: J Clin Oncol Date: 1990-05 Impact factor: 44.544
Authors: Farhad Ravandi; Jeffrey L Jorgensen; Susan M O'Brien; Elias Jabbour; Deborah A Thomas; Gautam Borthakur; Rebecca Garris; Xuelin Huang; Guillermo Garcia-Manero; Jan A Burger; Alessandra Ferrajoli; William Wierda; Tapan Kadia; Nitin Jain; Sa A Wang; Sergei Konoplev; Partow Kebriaei; Richard E Champlin; Deborah McCue; Zeev Estrov; Jorge E Cortes; Hagop M Kantarjian Journal: Br J Haematol Date: 2015-10-22 Impact factor: 6.998
Authors: Ryan D Cassaday; D Alan Potts; Philip A Stevenson; Merav Bar; George E Georges; Andrei R Shustov; Mohamed L Sorror; Brent L Wood; Colleen Delaney; Kristine C Doney; Rainer F Storb; Brenda M Sandmaier Journal: Leuk Lymphoma Date: 2016-03-22